Nuvectis Pharma (NVCT) Free Cash Flow (2021 - 2026)

Nuvectis Pharma has disclosed Free Cash Flow across 6 years of filings, most recently posting -$6.5 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$6.5 million, down 55.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.3 million (down 52.08% YoY), and the FY2025 annual result was -$16.0 million, down 30.72% from the prior year.
• Free Cash Flow came in at -$6.5 million for Q1 2026 at Nuvectis Pharma, down from -$4.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$2.4 million in Q3 2024 to a low of -$6.5 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$3.8 million (2023), against an average of -$3.8 million.
• Across the five-year window, Free Cash Flow tumbled 229.52% in 2022 and jumped 35.97% in 2024, its largest moves.
• Nuvectis Pharma's Free Cash Flow stood at -$3.5 million in 2022, then slipped by 9.5% to -$3.8 million in 2023, then soared by 35.97% to -$2.5 million in 2024, then sank by 61.22% to -$4.0 million in 2025, then tumbled by 63.84% to -$6.5 million in 2026.
• The last three Free Cash Flow figures came in at -$6.5 million (Q1 2026), -$4.0 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.